Showing results (41-50 of 199) with videos related to

Sort By:
Pageof 20
Haematologica|April 5, 2008
Follow-up of healthy donors receiving granulocyte colony-stimulating factor for peripheral blood progenitor cell mobilization and collection. Results of the Spanish Donor RegistryJavier de la Rubia, Felipe de Arriba, Cristina Arbona, et al.
Journal of Clinical Medicine|August 28, 2025
Absence of Red Blood Cell Alloimmunization in Transfused Patients Receiving Daratumumab: Experience from a Single CenterLara Eritzpokhoff, Ernesto Talegón De La Fuente, Aida Carril Barcia, et al.
Cancers|December 30, 2025
The Rise of Fine-Tuned CAR-Based Therapies Against Acute Myeloid LeukemiaAlejandro Segura Tudela, Ron Geller, Bruno Paiva, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 10, 2026
Real-World Outcomes of Melflufen Plus Dexamethasone in Heavily Pretreated Relapsed/Refractory Multiple Myeloma After Exposure to ImmunotherapiesDavid Martínez-Campuzano, Clara Sopeña, María José Moreno, et al.
Emergencias : Revista De La Sociedad Espanola De Medicina De Emergencias|February 9, 2023
Immune thrombotic thrombocytopenic purpura: clinical suspicion and basic management in emergency departments - an expert review and consensus statement from the Spanish societies of hematology and hemotherapy (SEHH) and emergency medicine (SEMES)Cristina Pascual-Izquierdo, Pascual Piñera Salmerón, Francisco Temboury Ruiz, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 18, 2012
Intravenous busulfan and melphalan as a conditioning regimen for autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: a matched comparison to a melphalan-only approachMargarita Blanes, Juan J Lahuerta, José D González, et al.
Research and Practice in Thrombosis and Haemostasis|September 2, 2024
Caplacizumab improves clinical outcomes and is well tolerated across clinically relevant subgroups of patients with immune-mediated thrombotic thrombocytopenic purpuraKaterina Pavenski, Marie Scully, Paul Coppo, et al.
Haematologica|June 2, 2009
Impact of hematopoietic chimerism at day +14 on engraftment after unrelated donor umbilical cord blood transplantation for hematologic malignanciesFederico Moscardó, Jaime Sanz, Leonor Senent, et al.
Journal of Clinical Medicine|May 27, 2023
Transfusion Burden in Allogeneic Hematopoietic Stem Cell Transplantation over Time: Experience from a Single InstitutionPilar Solves, Javier Marco-Ayala, Miguel Ángel Sanz, et al.
Leukemia & Lymphoma|December 11, 2007
Characteristics of and risk factors for pneumonia in patients with hematological malignancies developing fever after autologous blood stem cell transplantationNoemí Puig, Javier De La Rubia, Isidro Jarque, et al.
Pageof 20